<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma" /><meta property="og:locale" content="en" /><meta name="description" content="Rationale and Objectives" /><meta property="og:description" content="Rationale and Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/the-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/the-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2016-08-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2016-08-31T17:00:00+00:00","description":"Rationale and Objectives","headline":"The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/the-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d/"},"url":"https://clinicaltree.github.io/posts/the-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d/"}</script><title>The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>The Development of Reduced Diffusion Following Bevacizumab Therapy Identifies Regions of Recurrent Disease in Patients with High-grade Glioma</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1472662800" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Aug 31, 2016 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Ramon F. Barajas MD</a> </em>, <em> <a href="">Nicholas A. Butowski MD</a> </em>, <em> <a href="">Joanna J. Phillips MD PhD</a> </em>, <em> <a href="">Manish K. Aghi MD PhD</a> </em>, <em> <a href="">Mitchel S. Berger MD</a> </em>, <em> <a href="">Susan M. Chang MD</a> </em>, <em> <a href="">Soonmee Cha MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2191 words"> <em>12 min</em> read</span></div></div></div><div class="post-content"><h2 id="rationale-and-objectives"><span class="mr-2">Rationale and Objectives</span><a href="#rationale-and-objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The treatment of glioma with bevacizumab results in decreased enhancement, making it challenging to diagnose tumor recurrence. Therefore, the primary aim of this retrospective study was to determine if the underlying biological processes occurring within regions of recurrent glioblastoma in patients undergoing bevacizumab therapy influence morphologic and diffusion-weighted magnetic resonance (MR) imaging characteristics.</p><h2 id="materials-and-methods"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>In this Health Insurance Portability and Accountability Act–compliant and institutional review board–approved study, 26 patients treated with bevacizumab for high-grade glioma underwent lesion-wide apparent diffusion coefficient analysis before therapy and at the time of clinical/radiological progression, allowing for stratification by the presence or absence of reduced diffusion. Lesions with reduced diffusion were classified into “block” or “salt &amp; pepper” phenotypes. Eight of the 26 patients underwent image-guided tissue sampling at the time of suspected disease recurrence allowing for direct biological correlation. Clinical, histologic, and MR imaging differences between diffusion groups were assessed using a two-sample Welch <em>t</em> test.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>All patients had histologic evidence of recurrent disease with or without a background of treatment effect. Sixty-two percent of the cohort had developed reduced diffusion at clinical progression following bevacizumab. Image-guided tissue sampling demonstrated that treatment effect was not observed within regions of reduced diffusion. Recurrent tumor intermixed with treatment effect was more likely to be observed within the “salt &amp; pepper” phenotype when compared to “block” phenotype.</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Following bevacizumab therapy, recurrent glioblastoma can manifest as nonenhancing regions characterized by reduced diffusion. Histologically, these MR imaging characteristics correlate with aggressive biological features of disease recurrence.</p><h2 id="introduction"><span class="mr-2">Introduction</span><a href="#introduction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>High-grade glioma is the malignant form of primary glial neoplasms; the presence of which forebodes poor prognosis. Vascular endothelial growth factor, a hypoxia-regulated gene, is a powerful mediator of tumor progression via its role in tumor angiogenesis and vascular hyperplasia. Bevacizumab, a nonselective monoclonal antibody (mAb) for vascular endothelial growth factor, is clinically used for its antiangiogenic properties in patients with recurrent high-grade glioma.</p><p>Currently, the post-therapeutic radiological diagnosis of high-grade glioma recurrence is, in part, characterized by progressive contrast enhancement on serial magnetic resonance (MR) imaging. The presence of contrast enhancement is predicated on the expression of leaky microvasculature. The antiangiogenic effects of bevacizumab histologically causes pseudonormalization of the tumor microvasculature that is biologically manifested as reduced vascular permeability, reduced interstitial pressure, and diminished contrast-enhancing volume on MR imaging. As a result, it can be clinically challenging, in the setting of concurrent bevacizumab administration, to determine whether increasing T2 hyperintensity within a region of diminishing contrast enhancement is a hallmark of tumor response to therapy or the development of nonenhancing recurrent tumor.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="materials-and-methods-1"><span class="mr-2">Materials and Methods</span><a href="#materials-and-methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-population"><span class="mr-2">Patient Population</span><a href="#patient-population" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 1</p><p>Clinical and Qualitative MR Imaging Measurements</p><p>Patient Number Initial Dx Age Image-guided Tissue Sample KPS Pathology Group Concurrent Therapies Location SVZ Post Tx T2 Pattern DWI Phenotype 1 GBM 53 N 90 Recurrent Rd CPT, Carbo F 3 I S 2 GBM 50 N 80 Recurrent Rd CPT F 3 I S 3 GBM 50 N 90 Mixed Rd Carbo F 3 E S 4 GBM 64 N 80 Mixed Rd None O 3 I S 5 GBM 50 N 90 Recurrent Rd TMZ T 1 I B 6 GBM 63 N 90 Mixed Rd CPT P 3 E S 7 GBM 42 N 70 Recurrent Rd CPT T 4 I B 8 GBM 62 N 70 Recurrent Rd CPT P 1 I S 9 GBM 64 Y 70 Recurrent Rd None P 1 I B 10 AO 54 Y 90 Mixed Rd CPT F 3 I B 11 AOA 47 Y 90 Mixed Rd CPT P 2 I S 12 GBM 38 Y 90 Recurrent Rd TMZ F 3 I S 13 AO 56 Y 70 Recurrent Rd None P 3 I B 14 GBM 57 Y 80 Mixed Rd TMZ F 3 I S 15 GBM 62 Y 80 Recurrent Rd None P 1 I S 16 GBM 51 Y 90 Recurrent Rd None P 1 I B 17 GBM 52 N 90 Recurrent NRd Carbo T 3 E None 18 GBM 58 N 80 Recurrent NRd CPT P 2 E None 19 GBM 64 N 80 Recurrent NRd CPT T 3 E None 20 GBM 27 N 90 Recurrent NRd TMZ P 4 E None 21 GBM 35 N 90 Recurrent NRd TMZ T 4 I None 22 GBM 47 N 90 Recurrent NRd CPT P 4 I None 23 GBM 68 N 90 Mixed NRd None P 4 E None 24 GBM 58 N 90 Recurrent NRd None F 1 E None 25 GBM 56 N 80 Recurrent NRd None P 4 E None 26 GBM 47 N 90 Recurrent NRd CPT F 4 E None</p><p>AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; B, block; CPT, irinotecan, carbo, Paraplatin; DWI phenotype, reduced diffusion-weighted imaging phenotype; E, edematous; F, frontal; GBM, glioblastoma; I, infiltrative; Initial Dx, initial histologic diagnosis; KPS, Karnofsky Performance Scale Index (obtained before initiation of bevacizumab); Mixed, recurrent glioblastoma within background of treatment change/effect; NRd, nonreduced diffusion; O, occipital; P, parietal; Pathology, pathologic diagnosis at time of recurrence following Avastin; Post Tx T2 Pattern, post-bevacizumab therapy T2 pattern; Rd, reduced diffusion; Recurrent, recurrent glioblastoma; S, salt &amp; pepper; SVZ, subventricular zone; T, temporal; Tissue Sample, underwent image-guided tissue sampling, Yes or No; TMZ, temozolomide; Type 1, enhancement contacting cortex and subventricular zone; Type 2, enhancement contacting subventricular zone alone; Type 3, enhancement contacting cortex alone; Type 4, no enhancement of the cortex or subventricular zone.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mr-imaging-protocol"><span class="mr-2">MR Imaging Protocol</span><a href="#mr-imaging-protocol" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="morphologic-mr-imaging-characterization"><span class="mr-2">Morphologic MR Imaging Characterization</span><a href="#morphologic-mr-imaging-characterization" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="diffusion-weighted-mr-imaging-analysis"><span class="mr-2">Diffusion-weighted MR Imaging Analysis</span><a href="#diffusion-weighted-mr-imaging-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/0_1s20S1076633216300721.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/0_1s20S1076633216300721.jpg" alt="Figure 1, Development of block phenotype reduced diffusion in a 50-year-old man following 3 months of bevacizumab therapy. (a) Pre-therapeutic T1-weighted contrast-enhanced ( left ), axial fluid-attenuated inversion recovery (FLAIR) ( center left ), diffusion-weighted image ( center right ), and apparent diffusion coefficient (ADC) map ( right ) show no indication of reduced diffusion. (b) Post-therapeutic magnetic resonance (MR) imaging demonstrates interval development of mass like infiltrative minimally enhancing T2 hyperintensity and block phenotype reduced diffusion involving the right temporal lobe (lesion average T2 ADCmin = 350, ADCmean = 967, rADC min = 0.49, and rADCmean = 1.1). Pre-contrast T1-weighted images ( not shown ) did not demonstrate T1-shortening/blood products that would account for artificially reduced diffusion. Robust contrast enhancement predominately involving the anterior temporal lobe is not associated with reduced diffusion. (c) Image-guided tissue sampling of reduced diffusion lesion ( left ; T1 postcontrast sampling site, center ; ADC map, right ; hematoxylin and eosin [H&amp;E]) showed heterogeneous highly cellular recurrent tumor with some samples demonstrating increased cellular necrosis (H&amp;E stain, 10× Mmagnification; top and bottom samples; greater than 50%) when compared to regions demonstrating densely cellular tumor recurrence without necrosis ( middle sample ). Markedly elevated measures of cellular proliferation, vascular hyperplasia, and necrosis were also observed within regions of reduced diffusion when compared to regions without reduced diffusion ( not shown )." class="lazyload" data-proofer-ignore></a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/1_1s20S1076633216300721.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/1_1s20S1076633216300721.jpg" alt="Figure 2, Development of salt &amp; pepper phenotype reduced diffusion in a 57-year-old woman following 2 months of bevacizumab therapy. (a) Pre-therapeutic T1-weighted contrast-enhanced ( left ), axial fluid-attenuated inversion recovery (FLAIR) ( center left ), diffusion-weighted image ( center right ), and apparent diffusion coefficient (ADC) map ( right ) show no indication of reduced diffusion. Note the region of artificially reduced diffusion along the medial aspect of the resection cavity due to blood products that subsequently resolved. (b) Post-bevacizumab magnetic resonance (MR) imaging demonstrates interval development of mass like infiltrative T2 hyperintensity involving the frontal lobe with extension into the cingulate gyrus and genu of the corpus callosum associated with salt &amp; pepper phenotype reduced diffusion (lesion average T2 ADCmin = 665, ADCmean = 1082, rADC min = 0.95, and rADCmean = 1.3). Minimal contrast enhancement involves the region of reduced diffusion. (c) Image-guided tissue sampling of the lesion ( left ; T1 post contrast sampling site, center ; ADC map, right ; hematoxylin and eosin [H&amp;E]) showed heterogeneous regions of recurrent tumor and treatment-related changes (H&amp;E stain; 200× magnification). Tissue sample #3 ( bottom ), corresponding to a region of reduced diffusion, demonstrated infiltrating recurrent tumor with minimal necrosis. Tissue samples #1 and #2 ( top and middle ) corresponded to regions without reduced diffusion. Tissue sample #1 demonstrated infiltrating recurrent tumor margin with minimal necrosis. Tissue sample #2 demonstrated extensive necrosis without evidence of recurrent tumor most consistent with treatment effect." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mr-image-guided-biopsy-collection-and-processing"><span class="mr-2">MR Image-guided Biopsy Collection and Processing</span><a href="#mr-image-guided-biopsy-collection-and-processing" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patient-population-1"><span class="mr-2">Patient Population</span><a href="#patient-population-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="distinct-patterns-of-disease-recurrence-following-bevacizumab-therapy-are-stratified-by-morphologic-and-diffusion-weighted-mr-imaging-characteristics"><span class="mr-2">Distinct Patterns of Disease Recurrence Following Bevacizumab Therapy Are Stratified by Morphologic and Diffusion-weighted MR Imaging Characteristics</span><a href="#distinct-patterns-of-disease-recurrence-following-bevacizumab-therapy-are-stratified-by-morphologic-and-diffusion-weighted-mr-imaging-characteristics" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>Comparison of Pre- and Post-therapeutic Diffusion-weighted Imaging for All Patients</p><p>T2 Area T2 T2 T2 CE Area CE CE CE (cm 2 ) rADC min rADC mean rADC max (cm 2 ) rADC min rADC mean rADC max PreTx 13.4(12.2) 0.99(0.15) 1.66(0.34) 2.12(0.40) 2.36(2.94) 1.12(0.33) 1.51(0.23) 1.88(0.43) PostTx 17.7(9.8) 0.71(0.21) 1.30(0.18) 2.02(0.54) 3.82(7.08) 0.82(0.23) 1.20(0.33) 1.61(0.55)<em>P</em> value 0.16 0.01 0.01 0.41 0.34 0.01 0.01 0.05</p><p>CE, contrast enhancing region of interest; Mean (standard deviation), T2, T2 FLAIR hyperintensity region of interest; PostTx, following bevacizumab administration; PreTx, before bevacizumab administration.</p><p>Table 3</p><p>Comparison Diffusion-weighted Imaging Values for Reduced Diffusion Group</p><p>T2 Area T2 T2 T2R CE Area CE CE CE (cm 2 ) rADC min rADC mean rADC max (cm 2 ) rADC min rADC mean rADC max PreTx 17.3(13.0) 0.95(0.15) 1.71(0.41) 2.06(0.35) 3.25(3.43) 1.01(0.18) 1.46(0.23) 1.81(0.35) PostTx 20.5(9.91) 0.58(0.13) 1.21 0.13) 1.88(0.59) 4.49(8.69) 0.69(0.17) 1.05(0.13) 1.35(0.59)<em>P</em> value 0.44 0.01 0.01 0.30 0.60 0.01 0.01 0.01</p><p>CE, contrast enhancing region of interest; Max, maximum value; Mean, average value; Mean (standard deviation), T2, T2 FLAIR hyperintensity region of interest; Min, minimum value; PostTx, following bevacizumab administration; PreTx, before bevacizumab administration.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="adc-metrics-and-lesion-biological-characteristics-within-regions-of-treatment-effect-are-significantly-different-from-those-composed-of-recurrent-glioblastoma"><span class="mr-2">ADC Metrics and Lesion Biological Characteristics Within Regions of Treatment Effect Are Significantly Different From Those Composed of Recurrent Glioblastoma</span><a href="#adc-metrics-and-lesion-biological-characteristics-within-regions-of-treatment-effect-are-significantly-different-from-those-composed-of-recurrent-glioblastoma" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 4</p><p>Comparison of Diffusion-weighted Imaging and Cellular Proliferation Metrics Between Regions with Recurrent Tumor and Treatment Effect</p><p>ADC min ADC mean ADC max rADC min rADC mean rADC max Ki-67 RT 541(179) 711(206) 892(260) 0.96(0.21) 0.93(0.23) 0.94(0.31) 16.3(13.5) TE 838(78) 1154(110) 1455(257) 1.36(0.36) 1.62(0.35) 1.76(0.31) 1.7(1.63)<em>P</em> value &lt;0.01 &lt;0.01 &lt;0.01 0.04 &lt;0.01 &lt;0.01 &lt;0.01</p><p>ADC, apparent diffusion coefficient; Ki-67, expressed in percentage; rADC, relative apparent diffusion coefficient; RT, recurrent tumor; TE, treatment effect.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="regions-of-recurrent-glioblastoma-following-bevacizumab-therapy-characterized-by-reduced-diffusion-demonstrate-markedly-different-biological-properties-compared-to-regions-of-recurrent-tumor-without-reduced-diffusion"><span class="mr-2">Regions of Recurrent Glioblastoma Following Bevacizumab Therapy Characterized by Reduced Diffusion Demonstrate Markedly Different Biological Properties Compared to Regions of Recurrent Tumor without Reduced Diffusion</span><a href="#regions-of-recurrent-glioblastoma-following-bevacizumab-therapy-characterized-by-reduced-diffusion-demonstrate-markedly-different-biological-properties-compared-to-regions-of-recurrent-tumor-without-reduced-diffusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/2_1s20S1076633216300721.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/2_1s20S1076633216300721.jpg" alt="Figure 3, Histopathologic correlation of recurrent glioblastoma tissue samples obtained from regions with and without reduced diffusion using image-guided stereotactic neurosurgical techniques in a patient demonstrating salt &amp; pepper phenotype following bevacizumab therapy. (a) Intraoperative tissue sampling site superimposed on a post-therapeutic T1-weighted contrast-enhanced image, diffusion-weighted image, and apparent diffusion coefficient (ADC) map demonstrates mass like infiltrative T2 hyperintensity involving the left frontal lobe associated with salt &amp; pepper phenotype reduced diffusion and minimal contrast enhancement. Tissue sampling site from region without reduced diffusion ( left ) demonstrated ADC min of 842 and ADC mean of 951. Tissue sampling site from region with reduced diffusion demonstrated ADC min of 485 and ADC mean of 646 ( right ). (b) Tissue samples obtained from region of recurrent tumor without reduced diffusion ( blue region of interest [ROI] ) demonstrated infiltrating cellular tumor ( left ; H&amp;E stain 200× magnification), cellular proliferation of 1% ( middle ; Ki-67), with minimal vascular hyperplasia ( right ; factor VIII = delicate vascular appearance). (c) Tissue samples obtained from region of recurrent tumor with reduced diffusion ( red ROI ) demonstrated infiltrating cellular tumor ( left ; H&amp;E stain 10× magnification) with elevated cellular proliferation ( middle ; Ki-67 = 11%), and predominantly simple vascular hyperplasia ( right ; factor VIII). No significant necrosis was observed within either tissue specimens. (Color version of figure is available online.)" class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/3_1s20S1076633216300721.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/TheDevelopmentofReducedDiffusionFollowingBevacizumabTherapyIdentifiesRegionsofRecurrentDiseaseinPatientswithHighgradeGlioma/3_1s20S1076633216300721.jpg" alt="Figure 4, Recurrent glioblastoma following bevacizumab therapy with block phenotype reduced diffusion demonstrates elevated cellular proliferation. (a–c) Post-therapeutic T1-weighted contrast enhanced ( left ), axial fluid-attenuated inversion recovery (FLAIR) ( center left ), diffusion-weighted image ( center right ), and apparent diffusion coefficient (ADC) map ( right ) demonstrate mass like infiltrative T2 hyperintensity involving the frontal operculum associated with block phenotype reduced diffusion and minimal contrast enhancement. All tissue sampling sites were obtained within regions of reduced diffusion (ADC min A–C = 315, 336, and 246; ADC mean A–C = 365, 406, and 287; color circle region of interest [ROI]). Immunohistochemical analysis demonstrated markedly elevated cellular proliferation (Ki-67 A–C = 32%, 26%, and 29%, brown-stained cells; right column) irrespective of the presence (biopsy site C) or absence (biopsy sites A and B) of contrast enhancement. Additionally, elevated necrosis (H&amp;E, less than 50%; not shown) was observed. (Color version of figure is available online.)" class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="phenotypic-patterns-of-reduced-diffusion-are-associated-with-histopathologic-characteristics-of-recurrent-disease"><span class="mr-2">Phenotypic Patterns of Reduced Diffusion Are Associated with Histopathologic Characteristics of Recurrent Disease</span><a href="#phenotypic-patterns-of-reduced-diffusion-are-associated-with-histopathologic-characteristics-of-recurrent-disease" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="pre-bevacizumab-mr-imaging-characteristics-are-predictive-of-reduced-diffusion-development-following-bevacizumab-therapy"><span class="mr-2">Pre-bevacizumab MR Imaging Characteristics Are Predictive of Reduced Diffusion Development Following Bevacizumab Therapy</span><a href="#pre-bevacizumab-mr-imaging-characteristics-are-predictive-of-reduced-diffusion-development-following-bevacizumab-therapy" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="conclusion"><span class="mr-2">Conclusion</span><a href="#conclusion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="acknowledgements"><span class="mr-2">Acknowledgements</span><a href="#acknowledgements" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="appendix"><span class="mr-2">Appendix</span><a href="#appendix" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="supplementary-material"><span class="mr-2">Supplementary material</span><a href="#supplementary-material" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table S1</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Rieger J., Bähr O., Müller K., et. al.: Bevacizumab-induced diffusion-restricted lesions in malignant glioma patients. J Neurooncol 2010; 99: pp. 49-56.</p><li><p>2. Gerstner E.R., Frosch M.P., Batchelor T.T.: Diffusion magnetic resonance imaging detects pathologically confirmed, nonenhancing tumor progression in a patient with recurrent glioblastoma receiving bevacizumab. J Clin Oncol 2010; 28: pp. e91-e93.</p><li><p>3. Jain R., Scarpace L.M., Ellika S., et. al.: Imaging response criteria for recurrent gliomas treated with bevacizumab: role of diffusion weighted imaging as an imaging biomarker. J Neurooncol 2010; 96: pp. 423-431.</p><li><p>4. Pope W.B., Kim H.J., Huo J., et. al.: Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology 2009; 252: pp. 182-189.</p><li><p>5. Barajas R.F., Hodgson J.G., Chang J.S., et. al.: Glioblastoma multiforme regional genetic and cellular expression patterns: influence on anatomic and physiologic MR imaging. Radiology 2010; 254: pp. 564-576.</p><li><p>6. Le Bihan D., Turner R., Douek P., et. al.: Diffusion MR imaging: clinical applications. AJR Am J Roentgenol 1992; 159: pp. 591-599.</p><li><p>7. Rowley H.A., Grant P.E., Roberts T.P.: Diffusion MR imaging: theory and applications. Neuroimaging Clin N Am 1999; 9: pp. 343-361.</p><li><p>8. Le Bihan D., Breton E., Lallemand D., et. al.: MR imaging of intravoxel incoherent motions: application to diffusion and perfusion in neurologic disorders. Radiology 1986; 161: pp. 401-407.</p><li><p>9. Guo A.C., Cummings T.J., Dash R.C., et. al.: Lymphomas and high-grade astrocytomas: comparison of water diffusibility and histologic characteristics. Radiology 2002; 224: pp. 177-183.</p><li><p>10. Therasse P., Arbuck S.G., Eisenhauer E.A., et. al.: New guidelines to evaluate the response to treatment in solid tumors: European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: pp. 205-216.</p><li><p>11. Macdonald D.R., Cascino T.L., Schold S.C., et. al.: Response criteria for phase II studies of malignant glioma. J Clin Oncol 1990; 8: pp. 1277-1280.</p><li><p>12. Norden A.D., Young G.S., Setayesh K., et. al.: Bevacizumab for recurrent malignant gliomas; efficacy, toxicity, and patterns of recurrence. Neurology 2008; 70: pp. 779-787.</p><li><p>13. Iwamoto F.M., Abrey L.E., Beal K., et. al.: Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma. Neurology 2009; 73: pp. 1200-1206.</p><li><p>14. Verhoeff J., Tellingen O., Claes A., et. al.: Concerns about anti-angiogenic treatment in patients with glioblastoma multiforme. BMC Cancer 2009; 9: pp. 444.</p><li><p>15. Wen P.Y., Macdonald D.R., Reardon D.A., et. al.: Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 2010; 28: pp. 1963-1972.</p><li><p>16. Gupta A., Young R.J., Karimi S., et. al.: Isolated diffusion restriction precedes the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 2011; 32: pp. 1301-1306.</p><li><p>17. Barajas R.F., Pampaloni M.H., Clarke J.L., et. al.: Assessing biological response to bevacizumab using 18F-Fluoromisonidazole PET/MR imaging in a patient with recurrent anaplastic astrocytoma. Case Rep Radiol 2015; 2015: pp. 731361.</p><li><p>18. Pope W.B., Qiao X.J., Kim H.J., et. al.: Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol 2012; 108: pp. 491-498.</p><li><p>19. Ellingson B.M., Cloughesy T.F., Lai A., et. al.: Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol 2012; 106: pp. 111-119.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-23/'>Volume 23</a>, <a href='/categories/issue-9/'>Issue 9</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=The%20Development%20of%20Reduced%20Diffusion%20Following%20Bevacizumab%20Therapy%20Identifies%20Regions%20of%20Recurrent%20Disease%20in%20Patients%20with%20High-grade%20Glioma%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fthe-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=The%20Development%20of%20Reduced%20Diffusion%20Following%20Bevacizumab%20Therapy%20Identifies%20Regions%20of%20Recurrent%20Disease%20in%20Patients%20with%20High-grade%20Glioma%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fthe-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fthe-development-of-reduced-diffusion-following-bevacizumab-therapy-identifies-regions-of-recurrent-d%2F&text=The%20Development%20of%20Reduced%20Diffusion%20Following%20Bevacizumab%20Therapy%20Identifies%20Regions%20of%20Recurrent%20Disease%20in%20Patients%20with%20High-grade%20Glioma%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/assessment-of-heterogeneity-difference-between-edge-and-core-by-using-texture-analysis/"><div class="card-body"> <em class="small" data-ts="1472662800" data-df="ll" > Aug 31, 2016 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Assessment of Heterogeneity Difference Between Edge and Core by Using Texture Analysis</h3><div class="text-muted small"><p> Rationale and Objectives This study aimed to test the hypothesis that the heterogeneity difference between edge and core of lesions by using intensity and entropy features obtained from whole-lesi...</p></div></div></a></div><div class="card"> <a href="/posts/decreased-regional-cerebral-perfusion-at-resting-state-in-acute-posttraumatic-stress-disorder-result/"><div class="card-body"> <em class="small" data-ts="1472662800" data-df="ll" > Aug 31, 2016 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Decreased Regional Cerebral Perfusion at Resting State in Acute Posttraumatic Stress Disorder Resulting From a Single, Prolonged Stress Event</h3><div class="text-muted small"><p> Rationale and Objectives This study evaluated the altered regional cerebral blood flow (rCBF) in resting state in patients with acute posttraumatic stress disorder (PTSD) 3 months after trauma. M...</p></div></div></a></div><div class="card"> <a href="/posts/detecting-pulmonary-nodules-in-lung-cancer-patients-using-whole-body-fdg-pet-ct-high-resolution-lun/"><div class="card-body"> <em class="small" data-ts="1472662800" data-df="ll" > Aug 31, 2016 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Detecting Pulmonary Nodules in Lung Cancer Patients Using Whole Body FDG PET/CT, High-resolution Lung Reformat of FDG PET/CT, or Diagnostic Breath Hold Chest CT</h3><div class="text-muted small"><p> Rationale and Objectives Pulmonary nodules can be missed on the non-breath hold computed tomography (CT) portion of 18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG PET...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/the-abr-core-exam/" class="btn btn-outline-primary" prompt="Older"><p>The ABR Core Exam</p></a> <a href="/posts/the-validity-and-timing-of-the-abr-core-exam/" class="btn btn-outline-primary" prompt="Newer"><p>The Validity and Timing of the ABR Core Exam</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
